1 | prospective | 29,209 |
2 | uk-wide | 12 |
3 | study-a | 11 |
4 | two-phased | 10 |
5 | direct-comparison | 8 |
6 | retrospective-prospective | 7 |
7 | multicity | 6 |
8 | fair-hf | 5 |
9 | seven-centre | 5 |
10 | 12-center | 4 |
11 | by-patient | 4 |
12 | double-center | 4 |
13 | hertfordshire | 4 |
14 | one-pass | 4 |
15 | two-condition | 4 |
16 | .further | 3 |
17 | 15-site | 3 |
18 | 16-center | 3 |
19 | clinic-randomized | 3 |
20 | multicentral | 3 |
21 | school-randomized | 3 |
22 | teacher-taught | 3 |
23 | 10-center | 2 |
24 | 140-patient | 2 |
25 | 15-center | 2 |
26 | 160-channel | 2 |
27 | 195-patient | 2 |
28 | 2-state | 2 |
29 | 20-site | 2 |
30 | 27-center | 2 |
31 | 5½-year | 2 |
32 | 96-wk | 2 |
33 | bi-center | 2 |
34 | bicentric | 2 |
35 | controlled-human-exposure | 2 |
36 | difficult-to-use | 2 |
37 | dose-block | 2 |
38 | double-blind/double-dummy | 2 |
39 | dual-centre | 2 |
40 | extend-i | 2 |
41 | iride | 2 |
42 | one-centre | 2 |
43 | prospectic | 2 |
44 | recently-reported | 2 |
45 | self-run | 2 |
46 | source- | 2 |
47 | two-parallel-arm | 2 |
48 | 13-center | 1 |
49 | 2,201-patient | 1 |
50 | 21-night | 1 |
51 | 21-wk | 1 |
52 | 220-patient | 1 |
53 | 24-month-long | 1 |
54 | 264-week | 1 |
55 | 2×3-week | 1 |
56 | 30-campus | 1 |
57 | 30-site | 1 |
58 | 3070-subject | 1 |
59 | 31-site | 1 |
60 | 415-patient | 1 |
61 | 5-7-year | 1 |
62 | 54-center | 1 |
63 | 550-patient | 1 |
64 | 6,000-patient | 1 |
65 | 7543 | 1 |
66 | 94-week | 1 |
67 | 991-patient | 1 |
68 | bicentre | 1 |
69 | cbpr-driven | 1 |
70 | cctrn-designed | 1 |
71 | cea-registry | 1 |
72 | cleveland-based | 1 |
73 | closed-panel | 1 |
74 | community-cluster | 1 |
75 | cross-designed | 1 |
76 | currently-recruiting | 1 |
77 | decision-model-based | 1 |
78 | drug-hypersensitive | 1 |
79 | eighteen-month-long | 1 |
80 | fifty-six-week | 1 |
81 | first-in-men | 1 |
82 | gynecologic-oncology | 1 |
83 | hit4-1/mom1 | 1 |
84 | hiv-nat | 1 |
85 | lithium-placebo | 1 |
86 | mermaihd | 1 |
87 | moment.this | 1 |
88 | morbidity-based | 1 |
89 | multiple-cell | 1 |
90 | niaaa-funded | 1 |
91 | non-focused | 1 |
92 | paired-cluster | 1 |
93 | paired-facility | 1 |
94 | pcr-stratified | 1 |
95 | phase-iib | 1 |
96 | placebo-diet-controlled | 1 |
97 | prospectively-enrolled | 1 |
98 | prospectives | 1 |
99 | prospectıve | 1 |
100 | quasi-experiential | 1 |
101 | r01-level | 1 |
102 | reticulohistiocytosis | 1 |
103 | roster-trial | 1 |
104 | scaled-back | 1 |
105 | sfb/tr3/a1 | 1 |
106 | single-assessor-blinded | 1 |
107 | sodbi-sodbii | 1 |
108 | ssgxviii/aio | 1 |
109 | standardized-surgical-procedure | 1 |
110 | stramenopila | 1 |
111 | switching-replications | 1 |
112 | three-arms | 1 |
113 | three-condition | 1 |
114 | ti3n2 | 1 |
115 | treatment.additional | 1 |
116 | two-order | 1 |
117 | uni-blind | 1 |
118 | us-inclusive | 1 |
119 | us/uk | 1 |
120 | vif-cad | 1 |
121 | xd-1200n | 1 |
1 | .further | 3 |
2 | 10-center | 2 |
3 | 12-center | 4 |
4 | 13-center | 1 |
5 | 140-patient | 2 |
6 | 15-center | 2 |
7 | 15-site | 3 |
8 | 16-center | 3 |
9 | 160-channel | 2 |
10 | 195-patient | 2 |
11 | 2,201-patient | 1 |
12 | 2-state | 2 |
13 | 20-site | 2 |
14 | 21-night | 1 |
15 | 21-wk | 1 |
16 | 220-patient | 1 |
17 | 24-month-long | 1 |
18 | 264-week | 1 |
19 | 27-center | 2 |
20 | 2×3-week | 1 |
21 | 30-campus | 1 |
22 | 30-site | 1 |
23 | 3070-subject | 1 |
24 | 31-site | 1 |
25 | 415-patient | 1 |
26 | 5-7-year | 1 |
27 | 54-center | 1 |
28 | 550-patient | 1 |
29 | 5½-year | 2 |
30 | 6,000-patient | 1 |
31 | 7543 | 1 |
32 | 94-week | 1 |
33 | 96-wk | 2 |
34 | 991-patient | 1 |
35 | bi-center | 2 |
36 | bicentre | 1 |
37 | bicentric | 2 |
38 | by-patient | 4 |
39 | cbpr-driven | 1 |
40 | cctrn-designed | 1 |
41 | cea-registry | 1 |
42 | cleveland-based | 1 |
43 | clinic-randomized | 3 |
44 | closed-panel | 1 |
45 | community-cluster | 1 |
46 | controlled-human-exposure | 2 |
47 | cross-designed | 1 |
48 | currently-recruiting | 1 |
49 | decision-model-based | 1 |
50 | difficult-to-use | 2 |
51 | direct-comparison | 8 |
52 | dose-block | 2 |
53 | double-blind/double-dummy | 2 |
54 | double-center | 4 |
55 | drug-hypersensitive | 1 |
56 | dual-centre | 2 |
57 | eighteen-month-long | 1 |
58 | extend-i | 2 |
59 | fair-hf | 5 |
60 | fifty-six-week | 1 |
61 | first-in-men | 1 |
62 | gynecologic-oncology | 1 |
63 | hertfordshire | 4 |
64 | hit4-1/mom1 | 1 |
65 | hiv-nat | 1 |
66 | iride | 2 |
67 | lithium-placebo | 1 |
68 | mermaihd | 1 |
69 | moment.this | 1 |
70 | morbidity-based | 1 |
71 | multicentral | 3 |
72 | multicity | 6 |
73 | multiple-cell | 1 |
74 | niaaa-funded | 1 |
75 | non-focused | 1 |
76 | one-centre | 2 |
77 | one-pass | 4 |
78 | paired-cluster | 1 |
79 | paired-facility | 1 |
80 | pcr-stratified | 1 |
81 | phase-iib | 1 |
82 | placebo-diet-controlled | 1 |
83 | prospectic | 2 |
84 | prospective | 29,209 |
85 | prospectively-enrolled | 1 |
86 | prospectives | 1 |
87 | prospectıve | 1 |
88 | quasi-experiential | 1 |
89 | r01-level | 1 |
90 | recently-reported | 2 |
91 | reticulohistiocytosis | 1 |
92 | retrospective-prospective | 7 |
93 | roster-trial | 1 |
94 | scaled-back | 1 |
95 | school-randomized | 3 |
96 | self-run | 2 |
97 | seven-centre | 5 |
98 | sfb/tr3/a1 | 1 |
99 | single-assessor-blinded | 1 |
100 | sodbi-sodbii | 1 |
101 | source- | 2 |
102 | ssgxviii/aio | 1 |
103 | standardized-surgical-procedure | 1 |
104 | stramenopila | 1 |
105 | study-a | 11 |
106 | switching-replications | 1 |
107 | teacher-taught | 3 |
108 | three-arms | 1 |
109 | three-condition | 1 |
110 | ti3n2 | 1 |
111 | treatment.additional | 1 |
112 | two-condition | 4 |
113 | two-order | 1 |
114 | two-parallel-arm | 2 |
115 | two-phased | 10 |
116 | uk-wide | 12 |
117 | uni-blind | 1 |
118 | us-inclusive | 1 |
119 | us/uk | 1 |
120 | vif-cad | 1 |
121 | xd-1200n | 1 |
1 | source- | 2 |
2 | sfb/tr3/a1 | 1 |
3 | hit4-1/mom1 | 1 |
4 | ti3n2 | 1 |
5 | 7543 | 1 |
6 | study-a | 11 |
7 | stramenopila | 1 |
8 | phase-iib | 1 |
9 | bicentric | 2 |
10 | prospectic | 2 |
11 | vif-cad | 1 |
12 | single-assessor-blinded | 1 |
13 | niaaa-funded | 1 |
14 | pcr-stratified | 1 |
15 | prospectively-enrolled | 1 |
16 | placebo-diet-controlled | 1 |
17 | cctrn-designed | 1 |
18 | cross-designed | 1 |
19 | cleveland-based | 1 |
20 | decision-model-based | 1 |
21 | morbidity-based | 1 |
22 | two-phased | 10 |
23 | non-focused | 1 |
24 | recently-reported | 2 |
25 | clinic-randomized | 3 |
26 | school-randomized | 3 |
27 | mermaihd | 1 |
28 | uni-blind | 1 |
29 | iride | 2 |
30 | uk-wide | 12 |
31 | hertfordshire | 4 |
32 | one-centre | 2 |
33 | dual-centre | 2 |
34 | seven-centre | 5 |
35 | bicentre | 1 |
36 | standardized-surgical-procedure | 1 |
37 | controlled-human-exposure | 2 |
38 | difficult-to-use | 2 |
39 | 2-state | 2 |
40 | 20-site | 2 |
41 | 30-site | 1 |
42 | 31-site | 1 |
43 | 15-site | 3 |
44 | us-inclusive | 1 |
45 | prospective | 29,209 |
46 | retrospective-prospective | 7 |
47 | drug-hypersensitive | 1 |
48 | prospectıve | 1 |
49 | fair-hf | 5 |
50 | currently-recruiting | 1 |
51 | 24-month-long | 1 |
52 | eighteen-month-long | 1 |
53 | extend-i | 2 |
54 | sodbi-sodbii | 1 |
55 | scaled-back | 1 |
56 | dose-block | 2 |
57 | 2×3-week | 1 |
58 | 264-week | 1 |
59 | 94-week | 1 |
60 | fifty-six-week | 1 |
61 | us/uk | 1 |
62 | 21-wk | 1 |
63 | 96-wk | 2 |
64 | roster-trial | 1 |
65 | quasi-experiential | 1 |
66 | treatment.additional | 1 |
67 | multicentral | 3 |
68 | closed-panel | 1 |
69 | 160-channel | 2 |
70 | r01-level | 1 |
71 | multiple-cell | 1 |
72 | two-parallel-arm | 2 |
73 | xd-1200n | 1 |
74 | first-in-men | 1 |
75 | cbpr-driven | 1 |
76 | three-condition | 1 |
77 | two-condition | 4 |
78 | direct-comparison | 8 |
79 | self-run | 2 |
80 | lithium-placebo | 1 |
81 | ssgxviii/aio | 1 |
82 | 5-7-year | 1 |
83 | 5½-year | 2 |
84 | two-order | 1 |
85 | .further | 3 |
86 | 10-center | 2 |
87 | 12-center | 4 |
88 | 13-center | 1 |
89 | 54-center | 1 |
90 | 15-center | 2 |
91 | 16-center | 3 |
92 | 27-center | 2 |
93 | double-center | 4 |
94 | bi-center | 2 |
95 | paired-cluster | 1 |
96 | community-cluster | 1 |
97 | prospectives | 1 |
98 | moment.this | 1 |
99 | reticulohistiocytosis | 1 |
100 | three-arms | 1 |
101 | switching-replications | 1 |
102 | one-pass | 4 |
103 | 30-campus | 1 |
104 | hiv-nat | 1 |
105 | 3070-subject | 1 |
106 | 21-night | 1 |
107 | teacher-taught | 3 |
108 | 6,000-patient | 1 |
109 | 220-patient | 1 |
110 | 140-patient | 2 |
111 | 550-patient | 1 |
112 | 2,201-patient | 1 |
113 | 991-patient | 1 |
114 | 415-patient | 1 |
115 | 195-patient | 2 |
116 | by-patient | 4 |
117 | gynecologic-oncology | 1 |
118 | double-blind/double-dummy | 2 |
119 | cea-registry | 1 |
120 | multicity | 6 |
121 | paired-facility | 1 |